Abstract:Introduction: Pemphigus vulgaris (PV) is an autoimmune disease characterized by IgG autoantibodies targeting desmoglein-3 (Dsg3), leading to blistering of mucous membranes and skin. Although commercial ELISA kits effectively diagnose PV, correlation with clinical phenotype remains unclear. This study assesses multiple panels for monitoring disease severity and activity by profiling IgG autoantibodies against Dsg3's various extracellular ectodomains. Method: We designed and expressed different extracellular domains of Dsg3 in HEK293T cell line and developed 15 different ELISA panels, each using a single or multi ectodomains encompassing the entire extracellular region of Dsg3 to detect specific autoantibodies against the particular part of Dsg3. Results: To validate our approach, we compared our ELISA panel for the full Dsg3 (EC1-5) against a commercial kit using 154 random serum samples from PV patients, demonstrating a strong correlation. For evaluation of IgG autoantibody profiles in our panels, 59 PV patients were included, along with 11 bullous pemphigoid patients, and 49 healthy controls. For all the included subjects, 15 predefined ELISA panels were tested. The IgG autoantibodies against EC1 were detected in 86% of patients with a positive full Dsg3 ectodomain (EC1-5) ELISA, with 26% against EC2, 14% for EC3, 29% for EC4, and 23% for EC5. Among the panels with multiple Dsg3 ectodomains, EC1-3 and EC1-4 were representative of the entire Dsg3 ectodomain in terms of ELISA positivity across all included patients. A significant correlation (P<0.05) was observed between ELISA optical density (OD) and Pemphigus Disease Area Index (PDAI) scores in five panels, EC1, EC2-3, EC2-5, and EC3-4 in addition to the full ectodomain. It suggests an association with disease severity. Interestingly, while the ELISA panel for the entire Dsg3 extracellular ectodomains did not differentiate disease phases, in three of our panels, including EC1, EC3-5, and EC2-5, ANOVA analysis showed a statistically significant difference between the groups of patients in remission, partial remission or persistent lesions, and those with active disease (new cases or relapse). Among these three panels, EC1 was the only one that showed a significant difference in the multiple comparisons analysis; patients in the active phase had higher levels of autoantibodies than those in 'partial remission or persistent lesions' and 'complete remission' groups. Conclusion: The level of autoantibodies against EC1 was not only correlated with the full ectodomain but also associated with higher disease severity and active disease phase. This study indicates that a detailed autoantibody profile against Dsg3 ectodomains could serve as a marker for PV severity and activity which may potentially enhance early treatment initiation.

Detection of Antibody IgG Subclasses in Patients with Pemphigus Vulgaris and Their First Degree Relatives

Antigen-specific helper T cells in patients with pemphigus vulgaris

The Dysregulation of Circulating Innate Lymphoid Cells is Related to Autoantibodies in Pemphigus Vulgaris.

IgG reactivity to different desmoglein-3 ectodomains in pemphigus vulgaris: novel panels for assessing disease severity

Expression and Specific Antibody-Producing Capacity of B Lymphocytes Infiltrating in Lesions of Patients with Pemphigus Vulgaris

Use of serum anti-desmoglein-1 anti-desmoglein-3 antibodies in diagnosis of pemphigus vulgaris

The Study on Anti-Dsg1, Dsg3 Antibody Subclass Production and Cytokines Expression in the Patients with Paraneoplastic Pemphigus

Correlation between disease activity and pemphigus-specific antibody subclasses in patients with pemphigus

Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients

[Detection of Serum Desmoglein Antibody Level Using Enzyme-Linked Immunosorbent Assay (ELISA) for Monitoring Disease Activity in Patients with Pemphigus Vulgaris].

Fluctuations in Anti-Desmoglein Antibody Levels and Their Relationship with Disease Activity in Patients with Pemphigus

Comparison of serum cytokines and chemokines levels and clinical significance in patients with pemphigus vulgaris—A retrospective study

Current status and prospects for the diagnosis of pemphigus vulgaris

Serum Detection of Anti-thyroid Peroxidase and Anti-thyroglobulin Antibodies in Chinese Patients With Pemphigus Vulgaris and Pemphigus Foliaceus and Literature Review

Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris.

Shared VH1-46 Gene Usage by Anti-Desmoglein 3 Antibodies in Pemphigus Vulgaris Suggest a Common Mechanism for Developing Autoimmunity (BA2P.116)

Eukaryotic expression of pemphigus vulgaris autoantigen desmoglein 3 and its clinical application

Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages

Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.

Cognate Th2–B Cell Interaction is Essential for the Autoantibody Production in Pemphigus Vulgaris

Pathogenic Igg Antibodies Against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by Hla-Drb1*04:02-Restricted T Cells